Genzyme and Medtronic are out to prove that it doesn't just take time to heal a broken heart. The two companies' joint venture, MG Biotherapeutics, was created in 2004 to develop new treatments for heart attacks and other cardiovascular conditions. The company in 2006 ceased enrollment of new patients in its Phase II clinical trial, which had been testing the use of cell therapy to repair damaged heart tissue following a heart attack, after evidence showed the trial would not be successful. MG Biotherapeutics is also engaged in long-term research into next-generation cell therapies and is developing a less-invasive, catheter-based delivery system for cell therapy using Medtronic's TransAccess technology.

Abbott Laboratories company was founded in 1888 and is based in Abbott Park, Illinois. Abbott Laboratories manufactures and sells health care products worldwide. Abbott company's Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, dyslipidemia, HIV infection, hypothyroidism, advanced prostate cancer, endometriosis and central precocious puberty, anemia caused by uterine fibroids, obesity, epilepsy and bipolar disorder, migraines, and secondary hyperparathyroidism; and provides anesthesia products and anti-infectives. Its Diagnostic Products segment offers immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-based tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis.Abbott Company's Nutritional Products segment provides various forms of prepared infant formula and follow-on formula, adult and other pediatric nutritional products, nutritional products used in enteral feeding in health care institutions, and bars and nutritional brands. Its Vascular Products segment offers coronary, endovascular, and vessel closure devices, such as drug-eluting coronary stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, and carotid stent systems to treat vascular disease. Abbott serves wholesalers, government agencies, health care facilities, specialty pharmacies, independent retailers, hospitals, clinics, physicians' offices, blood banks, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and third-party distributors.

Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California. Aeolus Pharmaceuticals, Inc. (Aeolus) is a pharmaceutical company engaged in development of medical countermeasures against biological, chemical and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. The Company is testing its lead compound, AEOL 10150, in a range of indications each in various stages of development. The Company’s lead indications are a medical countermeasure against the effects of acute radiation syndrome (ARS) in the lungs and in the gastro-intestinal tract, and a medical countermeasure against the effects of sulfur mustard gas and chlorine gas. The Company is also developing its second drug candidate AEOL 11207 for the treatment of epilepsy and Parkinson’s disease.

CXR Biosciences Ltd. company was founded in 2001 and is based in Dundee, the United Kingdom. CXR Biosciences Ltd. provides drug development solutions and investigative toxicology services. Its drug development solutions include bioavailability, patient response variation, drug/drug interactions, drug reactions, toxicity, reactive metabolites, customized assay development, and anticancer drug development services. The company also offers mechanistic toxicology, collaborative research, and microarray services. In addition, it provides various preclinical screening systems that include Hepatic Reductase Null, which is used for determining the role of hepatic P450 metabolism in drug disposition; ToxReporter Mice for the mechanistic assessment of potential toxic effects in vivo; antioxidant response elements; ToxReporter cell lines for drug safety screening; and nuclear hormone receptor transactivation assays. Further, the company licenses its products.

Lifecore Biomedical hopes to help bodies plump up, smooth out, and keep moving. Lifecore's hyaluronan division makes products using hyaluronan, a natural lubricating compound found in animal and human connective tissues. The products are used in cataract surgeries, bone grafting, pain treatments for osteoarthritis, and veterinary orthopedics. Hyaluronan is also being tapped for use in cosmetic procedures as a dermal filler (to smooth out wrinkles). Lifecore has supply agreements with Alcon to use its hyaluronan solution in cataract surgery products. In 2008 the firm was taken private by Warburg Pincus.

Quidel Corporation was founded in 1979 and is based in San Diego, California. Quidel Corporation is engaged in the development, manufacturing and marketing of rapid diagnostic solutions for decentralized applications, including professional point-of-care (POC) in infectious diseases, reproductive and women’s health. The Company focuses on POC testing solutions specifically developed for the physician office lab (POL) and acute care markets globally. It sells its products to professionals for use in physician offices, hospitals, clinical laboratories and wellness screening centers. Its POC testing solutions are designed to provide specialized results that meet two value criteria that the Company has branded as Quidel Value Build (QVB). The Company provides rapid POC and other diagnostic tests under brand names, including QuickVue, QuickVue+, QuickVue Advance, Metra, Quidel and MicroVue. The Company markets its products in the United States through a network of national and regional distributors, supported by a direct sales force.

Forest Laboratories, Inc. was founded in 1956 and is based in New York, New York. Forest Laboratories, Inc. develops, manufactures, and sells branded and generic forms of ethical drug products. Its principal products include Lexapro to treat depression; Namenda to treat Alzheimer's disease; Bystolic, beta-blocker to treat hypertension; and Savella for the treatment of fibromyalgia. The company also provides Sudocrem, a topical preparation to treat diaper rash; Colomycin, an antibiotic to treat cystic fibrosis; Infacol, which is used to treat infant colic; and Exorex, which is to treat eczema and psoriasis. In addition, its products include Dutogliptin, a small molecule dipeptidyl-peptidase-4 inhibitor, which is in Phase III studies to treat Type II diabetes mellitus; F2695 that completed Phase II study and is a selective norepinephrine and serotonin reuptake inhibitor for the treatment of depression and other central nervous system disorders; and ceftaroline acetate, a injectable cephalosporin antibiotic that exhibits bactericidal activity against the strains of gram-positive bacteria.Forest Laboratories'sproducts comprise NXL104, an intravenous beta-lactamase inhibitor; Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation; Aclidinium, an inhaling therapy, which is in Phase III studies for chronic obstructive pulmonary disease; and Cariprazine, an atypical antipsychotic in Phase II(b) studies for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions. Additionally, its products include Oglemilast, a phosphodiesterase-IV inhibitor in Phase II study to treat COPD and asthma; and Benicar, an angiotensin receptor blocker to treat hypertension. The company has collaboration and license agreements Phenomix Corporation, Pierre Fabre Medicament, Novexel, S.A., Laboratorios Almirall, S.A., Gedeon Richter Ltd., Glenmark Pharmaceuticals Ltd., and AstraZeneca plc.

Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.

CeMines Biologics, LLC company is working on more accurate, simple blood tests to diagnose lung, breast, prostate, and other cancers. The firm's CeMines Molecular FingerPrinting technology uses biostatistics to determine if disease biomarkers found in a patient's blood sample indicate the likelihood of cancer. Its lead product candidate, CeMines CellCorrect LAb, detects patterns of key antibodies that indicate cancer cells are present. Noted researcher Toomas Neuman, whose use of stem cells to treat Parkinson's disease triggered a national debate, founded the company in 2000 with several other officers of the company, which is led by CEO Richard Cavalli.

Ore Pharmaceuticals Inc. company was founded in 1994 and is headquartered in Cambridge, Massachusetts. Ore Pharmaceutical Holdings Inc., through its wholly owned subsidiary, Ore Pharmaceuticals Inc., operates as a drug development company in the United States. Its drug candidates include GL1001, the lead drug candidate that completed a multiple ascending dose Phase I clinical trial, for the treatment of inflammatory bowel disease; tiapamil for treatment of diseases of central nervous system, primarily focused on cognition and memory; and romazarit, a clinical-stage drug candidate for the treatment of metabolic indications, such as obesity.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.